logo

For the Inventor, By the Inventor

Yokohama, Japan

Yoshiharu Morita

This inventor holds 20 USPTO granted patents, primarily in Anti-Tumor Agents. Top assignees: Mitsubishi Chemical Industries Limited, Merck + Co., Inc., Mitsubishi Kasei Corporation. Active years: 1976-1995.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yoshiharu Morita. Retrieved from https://idiyas.com/inventor/yoshiharu-morita

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20

% Patents Active = 100.0

Average Co-Inventor Count = 3.7

ph-index = 5

Forward Citations = 101(Granted Patents)


Location History:

  • Tokyo, JA (1976)
  • Yokohama, JP (1978 - 1995)

Company Filing History:

goldMedal12 out of 614 
 
Mitsubishi Chemical Industries Limited
 patents
silverMedal4 out of 4,770 
 
Merck + Co., Inc.
 patents
bronzeMedal4 out of 499 
 
Mitsubishi Kasei Corporation
 patents

Years Active: 1976-1995

Loading Chart...
Areas of Expertise:
Anti-Solid Tumor Agents
Phosphinic Acid Derivatives
Peptide Derivatives
Aminoethylphosphinic Acid
Benzylamine Derivative
Isoquinoline Derivatives
Phthalide Derivatives
Cysteine Derivatives
Penicillin Synthesis
Highly Unsaturated Compounds
20 patents (USPTO):Explore Patents
1. 5387609 - Anti-solid tumor agents (1995-02-07),
2. 5300525 - Anti-solid tumor agents (1994-04-05),
3. 5151521 - 1-aminoethyl phosphonic acid derivatives (1992-09-29),
4. 5061806 - Phosphinic acid derivatives (1991-10-29),
5. 5041644 - Peptide derivatives of .beta.-chloro-L(Z)-dehydro-glutamic acid (1991-08-20),
6. 5030732 - Aminoethylphosphinic acid derivatives (1991-07-09),
7. 4963684 - Process for preparing cotarnine (1990-10-16),
8. 4916160 - Anti-tumor promoter agents (1990-04-10),
9. 4769480 - Benzylamine derivative (1988-09-06),
10. 4760145 - Certain 6,7-methylene dioxydihydro or tetrahydro-isoquinoline derivatives (1988-07-26),
11. 4746747 - Anisole derivatives (1988-05-24),
12. 4684732 - Process for preparation of phthalide derivatives (1987-08-04),
13. 4622181 - Process for producing an estrone acetal (1986-11-11),
14. 4440788 - Cysteine derivatives (1984-04-03),
15. 4251442 - Method for synthesis of penicillin (1981-02-17),

Title: Yoshiharu Morita: A Pioneer in Anti-Solid Tumor Agents

Introduction

Yoshiharu Morita, based in Yokohama, Japan, is a distinguished inventor with an impressive portfolio of 20 patents. His work focuses primarily on the development of innovative anti-solid tumor agents that show promise in the fight against cancer. His contributions to the field combine scientific rigor with creative solutions to complex health challenges.

Latest Patents

Morita's latest inventions revolve around anti-solid tumor agents utilizing cembrane-type compounds. These agents are characterized by the general formulas (I) and (II), where R can be a hydrogen atom or an acyl group, serving as effective ingredients in cancer treatment formulations. His research plays a crucial role in enhancing therapeutic options for patients facing solid tumors.

Career Highlights

Throughout his career, Yoshiharu Morita has been associated with leading companies in the chemical and pharmaceutical sectors. Notably, he has worked at Mitsubishi Chemical Industries Limited and Merck & Company, Inc. His experience in these organizations has contributed significantly to his innovation and patent development.

Collaborations

Morita has collaborated with esteemed colleagues in his field, including Tadashi Shirasaka and Junichi Ohya. Their joint efforts have engineered advancements in the development of cancer treatment methodologies, fostering an environment of collaboration and innovation within the industry.

Conclusion

Yoshiharu Morita exemplifies the spirit of innovation that drives progress in the realm of medical research. With his extensive patent portfolio and collaborative spirit, he continues to make significant contributions to the field of oncology, ensuring a brighter future for cancer patients through effective treatment options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…